Skip to main content
SpringerLink
Log in

Paradigmenwechsel in der Onkologie

Fortschritte in der Immuntherapie

Progress in cancer immunotherapy

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Die Onkologie durchläuft eine Entwicklung, die die bisherige medikamentöse Tumortherapie in fast allen Bereiche verändern wird: Die Immuntherapie hält nach Jahrzehnten des Misserfolgs Einzug. Wie wirkt sie, wann ist sie indiziert, welche Nebenwirkungen können auftreten?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Heinrich B, Heinrich B, Brudler O, Bangerter M. [Chemotherapy is better than its reputation: important developments within the last decades]. MMW Fortschr Med. 2015 Aug 20;157(14):39–43.

    Article  PubMed  Google Scholar 

  2. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909;5:273–90.

    Google Scholar 

  3. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982;55(3-4):329–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1–27.

    Article  CAS  PubMed  Google Scholar 

  5. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988;334(6181):395–402.

    Article  CAS  PubMed  Google Scholar 

  6. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39(1):1–10.

    Article  PubMed  Google Scholar 

  7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Topalian SL, Drake CG, Pardoll DM. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer cell 2015;27(4):450–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2015;33(17):1889–94.

    Article  CAS  Google Scholar 

  10. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11(11):3887–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of experimental medicine 2000;192(7):1027–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer research 2004;64(3):1140–5.

    Article  CAS  PubMed  Google Scholar 

  13. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O’Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010;116(17):3268–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England journal of medicine 2012;366(26):2455–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515(7528):558–62.

    Article  CAS  PubMed  Google Scholar 

  16. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. The New England journal of medicine 2015;372(4):311–9.

    Article  PubMed  Google Scholar 

  17. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348(6230):124–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Mennitto A, Grassi P, Ratta R, Verzoni E, Prisciandaro M, Procopio G. Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Ther Adv Urol. 2016 Oct;8(5):319–326. Review. PubMed PMID: 27695530; PubMed Central PMCID: PMC5004235..

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lim JS, Soo RA. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. Ther Adv Respir Dis. 2016 Oct;10(5):444–54. doi: 10.1177/1753465816661091. Epub 2016 Jul 31. Review. PubMed PMID: 27480166.

    Article  CAS  PubMed  Google Scholar 

  20. Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C. The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. Ann Transl Med. 2016 Jun;4(11):215. doi: 10.21037/atm.2016.05.64. Review. PubMed PMID: 27386489; PubMed Central PMCID: PMC4916358.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Xia B, Herbst RS. Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy. 2016;8(3):279–98. doi: 10.2217/imt.15.123. Epub 2016 Feb 9. PubMed PMID: 26860624.

    Article  CAS  PubMed  Google Scholar 

  22. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320–30. doi

    Article  CAS  PubMed  Google Scholar 

  23. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 Nov 10;375(19):1856–1867. PubMed PMID: 27718784.

    Article  PubMed  Google Scholar 

  24. Suzanne Louise Topalian, Mario Sznol, Julie R. Brahmer, David F. McDermott, David C. Smith, Scott N. Gettinger, Janis M. Taube, Charles G. Drake, Drew M. Pardoll, John D. Powderly, Richard D. Carvajal, Jeffrey Alan Sosman, Michael B. Atkins, Scott J. Antonia, David R. Spigel, Donald P. Lawrence, Georgia Kollia, Ashok Kumar Gupta, Jon M. Wigginton, F. Stephen Hodi; Sidney Kimmel Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. 2013 ASCO Annual Meeting J Clin Oncol 31, 2013 (suppl; abstr 3002)

  25. Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016 Jan;13(1):25–40. doi: 10.1038/nrclinonc.2015.187. Epub 2015 Nov 3. Review. PubMed PMID: 26525683; PubMed Central PMCID: PMC4916838.

    Article  CAS  PubMed  Google Scholar 

  26. Badi Edmond El Osta, Fengjiao Hu, Ramses F. Sadek, Rohini Chintalapally, Shou-Ching Tang; Georgia Regents University Cancer Center, Augusta, GA; Augusta University, Augusta, GA Immune checkpoint inhibitors (ICI): A meta-analysis of immune-related adverse events (irAE) from cancer clinical trials. 2016 ASCO Annual Meeting J Clin Oncol 34, 2016 (suppl; abstr e14562)

  27. Proc ASCO 2016 J Clin Oncol 34, 2016

Download references

Author information

Authors and Affiliations

  1. Translationale Immuntherapie III. Medizinische Klinik, Klinikum rechts der Isar Technische Universität München, München, Deutschland

    Angela M. Krackhardt

  2. Brudler/Heinrich/Bangerter, Halderstraße 29, D-86150, Augsburg, Deutschland

    Bernhard Heinrich (Hämatologisch Onkologische Praxis)

Authors
  1. Angela M. Krackhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernhard Heinrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernhard Heinrich.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krackhardt, A.M., Heinrich, B. Fortschritte in der Immuntherapie. MMW - Fortschritte der Medizin 159, 48–53 (2017). https://doi.org/10.1007/s15006-017-9949-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9949-y

Keywords

Search

Navigation